Skip to content

house · Committee report

H. Rept. 119-816

COMBATING ILLICIT XYLAZINE ACT

2026-09-14

Committees

Associated legislation

Text

Purpose and Summary

H.R. 1266, the Combatting Illicit Xylazine Act, would designate xylazine as a Schedule III controlled substance under the Controlled Substances Act while still permitting its lawful use for legitimate veterinary purposes.

Background and Need for Legislation

Xylazine, commonly referred to as ``tranq,'' is a non- opioid sedative that was approved by the U.S. Food and Drug Administration (FDA) in 1972 for veterinary purposes.\1\ There are no approved human uses of xylazine.\2\ It is an important prescription sedative that facilitates the safe handling and treatment of many large animals, including pets, wildlife, zoo animals, and livestock.\3\ --------------------------------------------------------------------------- \1\Food and Drug Administration (FDA), What We're Doing to Stop Illicit Xylazine from Getting into the U.S. (Jul. 2023), https:// www.fda.gov/animal-veterinary/news-events/what-were-doing-stop-illicit- xylazine-getting-us; see also, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), Xylazine (Sept. 2024), https:/ /nida.nih.gov/research-topics/xylazine#legal. \2\Food and Drug Administration (FDA), Dear Colleague Letter, FDA warns about the risk of xylazine exposure in humans (Nov. 2022), https://www.fda.gov/media/162981/download?attachment. \3\Joanna R. Lampe, Cong. Rsch. Serv. (CRS), LSB11202, Xylazine and the Controlled Substances Act: Legal Considerations for Congress (2024). --------------------------------------------------------------------------- Though there are legitimate pathways for procuring xylazine for approved veterinary purposes, it can also be purchased online in either a liquid or powder form for illicit purposes.\4\ Xylazine has been more frequently detected in the illicit drug supply and has resulted in an increasing number of overdose deaths.\5\ Between 2018 and 2021, there was a 35-fold increase in the rate of drug overdoses involving xylazine.\6\ --------------------------------------------------------------------------- \4\Department of Justice (DOJ) & Drug Enforcement Administration (DEA), The Growing Threat of Xylazine and its Mixture with Illicit Drugs at 1 (Oct. 2022), https://www.dea.gov/sites/default/files/2022- 12/The%20Growing%20Threat%20of%20Xylazine%20and%20its%20 Mixture%20with%20Illicit%20Drugs.pdf. \5\DOJ & DEA, The Growing Threat of Xylazine and its Mixture with Illicit Drugs (Oct. 2022), https://www.dea.gov/sites/default/files/ 2022-12/The%20Growing%20Threat%20of%20Xylazine%20 and%20its%20Mixture%20with%20Illicit%20Drugs.pdf; see also Press Release, NIH, National Institute on Drug Abuse, Xylazine appears to worsen the life-threatening effects of opioids in rats (Jun. 2023), https://nida.nih.gov/news-events/news-releases/2023/06/xylazine- appears-to-worsen-the-life-threatening-effects-of-opioids-in-rats. \6\Centers for Disease Control and Prevention (CDC), National Center for Health Statistics, Drug Overdose Deaths Involving Xylazine: United States, 2018-2021 (Jun. 2025), https://www.cdc.gov/nchs/data/ vsrr/vsrr030.pdf. --------------------------------------------------------------------------- Xylazine is being increasingly utilized as a low cost adulterant to reduce the amount of fentanyl or heroin in a mixture, thereby increasing the profits of illicit drug traffickers.\7\ In 2024, the Drug Enforcement Administration (DEA) reported that xylazine is the most common drug mixed with fentanyl.\8\ When used as an adulterant in illicit drug mixtures, xylazine can attract those seeking to extend the duration of intoxication.\9\ However, many of those who consume xylazine are not aware they are doing so.\10\ On April 12, 2023, the White House Office of National Drug Control Policy designated fentanyl combined with xylazine as an emerging threat in the U.S.\11\ --------------------------------------------------------------------------- \7\DOJ & DEA, The Growing Threat of Xylazine and its Mixture with Illicit Drugs at 4 (Oct. 2022), https://www.dea.gov/sites/default/ files/2022-12/The%20Growing%20Threat%20of%20 Xylazine%20and%20its%20Mixture%20with%20Illicit%20Drugs.pdf. \8\DEA, 2025 National Drug Threat Assessment (May 2025), https:// www.dea.gov/sites/default/files/2025-07/ 2025NationalDrugThreatAssessment.pdf. \9\Supra note 4. \10\Id. \11\Press Release, The White House, Office of National Drug Control Policy, Biden-Harris Administration Designates Fentanyl Combined with Xylazine as an Emerging Threat to the United States (Apr. 2023), https://bidenwhitehouse.archives.gov/ondcp/briefing-room/2023/04/12/ biden-harris-administration-designates-fentanyl-combined-with-xylazine- as-an-emerging-threat-to-the-united-states/. --------------------------------------------------------------------------- H.R. 1266 would classify xylazine as a Schedule III controlled substance under the Controlled Substances Act, while permitting its legal use in authorized veterinary practices. While the Drug Enforcement Agency has some authority to tailor controls to specific substances, it cannot implement exemptions like those required for veterinary uses of xylazine through the regular scheduling process.\12\ The legislation would also require the Attorney General, through the Administrator of the Drug Enforcement Administration, to report to Congress on the trafficking and misuse of xylazine in the United States. --------------------------------------------------------------------------- \12\Lampe, supra note 3. ---------------------------------------------------------------------------

Committee Action

On March 26, 2026, the Subcommittee on Health held a hearing on H.R. 1266. The Subcommittee received testimony from: Scott Oulton, President, INTR3PID Solutions LLC K. Fred Gingrich II, DVM, Executive Director, American Association of Bovine Practitioners Dennis Lemma, Sheriff, Seminole County, Florida, and Former President of the Major County Sheriffs of America Nabarun Dasgupta, PhD, MPH, Senior Scientist and Gillings Innovation Fellow, University of North Carolina at Chapel Hill Yngvild Olsen, MD, MPH, Former Director of the Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, and National Advisor, Manatt Health On June 25, 2026, the Subcommittee on Health met in open markup session and forwarded H.R. 1266, without amendment, to the full Committee by a voice vote. On July 20 and 21, 2026, the full Committee on Energy and Commerce met in open markup session and ordered H.R. 1266, as amended, favorably reported to the House by a record vote of 48 yeas and 0 nays.

Committee Votes

Clause 3(b) of rule XIII requires the Committee to list the record votes on the motion to report legislation and amendments thereto. The following reflects the record votes taken during the Committee consideration: [GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT] Oversight Findings and Recommendations Pursuant to clause 2(b)(1) of rule X and clause 3(c)(1) of rule XIII, the Committee held (a) hearing(s) and made findings that are reflected in this report. New Budget Authority, Entitlement Authority, and Tax Expenditures Pursuant to clause 3(c)(2) of rule XIII, the Committee finds that H.R. 1266 would result in no new or increased budget authority, entitlement authority, or tax expenditures or revenues.

Congressional Budget Office Estimate

Pursuant to clause 3(c)(3) of rule XIII, at the time this report was filed, the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974 was not available. Federal Mandates Statement The Committee adopts as its own the estimate of Federal mandates prepared by the Director of the Congressional Budget Office pursuant to section 423 of the Unfunded Mandates Reform Act. Statement of General Performance Goals and Objectives Pursuant to clause 3(c)(4) of rule XIII, the general performance goal or objective of this legislation is to designate xylazine as a Schedule III controlled substance under the Controlled Substances Act while still permitting it to be used for legitimate veterinary purposes. Duplication of Federal Programs Pursuant to clause 3(c)(5) of rule XIII, no provision of H.R. 1266 is known to be duplicative of another Federal program, including any program that was included in a report to Congress pursuant to section 21 of Public Law 111-139 or the most recent Catalog of Federal Domestic Assistance. Related Committee and Subcommittee Hearings Pursuant to clause 3(c)(6) of rule XIII, the following related hearing was used to develop or consider H.R. 1266: On February 6, 2025, the Subcommittee on Health held a hearing on H.R. 1266. The title of the hearing was ``Combatting Existing and Emerging Illicit Drug Threats.'' The Subcommittee received testimony from: Sheriff Michael Bouchard, Vice President of Government Affairs, Major County Sheriffs Association; Mr. Raymond Cullen, Family Advocate; Dr. Timothy Westlake, MD, FFSMB, FACEP, Emergency Medicine Physician, ProHealth Care Oconomowoc Memorial Hospital; Ms. Regina LaBelle, JD, Professor and Director, Master of Science in Addiction Policy and Practice, Georgetown University; and, Dr. Deepa Camenga, MD, MHS, FAAP, Chair, Committee on Substance Use and Prevention, American Academy of Pediatrics. On March 26, 2026, the Subcommittee on Health held a hearing on H.R. 1266. The title of the hearing was ``Policies to Protect Our Communities From Illicit Drug Threats.'' The Subcommittee received testimony from: Scott Oulton, President, INTR3PID Solutions LLC; K. Fred Gingrich II, DVM, Executive Director, American Association of Bovine Practitioners; Dennis Lemma, Sheriff, Seminole County, Florida, and Former President of the Major County Sheriffs of America; Nabarun Dasgupta, PhD, MPH, Senior Scientist and Gillings Innovation Fellow, University of North Carolina at Chapel Hill; and, Yngvild Olsen, MD, MPH, Former Director of the Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, and National Advisor, Manatt Health. Committee Cost Estimate Pursuant to clause 3(d)(1) of rule XIII, the Committee adopts as its own the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974. At the time this report was filed, the estimate was not available. Earmark, Limited Tax Benefits, and Limited Tariff Benefits Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the Committee finds that H.R. 1266 contains no earmarks, limited tax benefits, or limited tariff benefits. Advisory Committee Statement No advisory committees within the meaning of section 5(b) of the Federal Advisory Committee Act were created by this legislation. Applicability to Legislative Branch The Committee finds that the legislation does not relate to the terms and conditions of employment or access to public services or accommodations within the meaning of section 102(b)(3) of the Congressional Accountability Act. Section-by-Section Analysis of the Legislation Section 1. Short title Section 1 provides a short title of ``Combating Illicit Xylazine Act''. Section 2. Definitions Section 2 defines ``xylazine'' within the Controlled Substances Act. Section 3. Adding xylazine to Schedule III Section 3 adds xylazine to Schedule III of the Controlled Substances Act. Section 4. Amendments Section 4 amends the definition of the ``ultimate user'' to create an exception that allows for the continued lawful use of xylazine prescribed or dispensed by a registered veterinarian. Section 4 clarifies the applicability of facility security standards, labeling standards, and practitioner registration requirements. This section also directs the FDA and DEA to expedite the relevant manufacturer submissions or applications required by the Schedule III status of xylazine. Section 5. ARCOS tracking Section 5 requires that xylazine be added to the Automation of Reports and Consolidated Orders System (ARCOS), which monitors DEA controlled substances including the manufacturing and distribution of Schedule III drugs. Section 6. Sentencing commission Section 6 requires the United States Sentencing Commission to review and make any appropriate amendments to the sentencing guidelines, policy statements, and official commentary relevant to convictions involving xylazine. Section 7. Report to Congress on xylazine Section 7 directs the DEA and FDA to submit a report to Congress that details the prevalence and impacts of the illicit use of xylazine in the United States, as well as information regarding the diversion of xylazine, and whether any analogues to xylazine exist and pose a significant risk of abuse. This Section also directs the DEA and FDA to submit an additional report to Congress not later than four years after the date of enactment regarding the prevalence and proliferation of xylazine trafficking and misuse in the U.S. Changes in Existing Law Made by the Bill, as Reported In compliance with clause 3(e) of rule XIII of the Rules of the House of Representatives, changes in existing law made by the bill, as reported, are shown as follows (existing law proposed to be omitted is enclosed in black brackets, new matter is printed in italics, and existing law in which no change is proposed is shown in roman): CONTROLLED SUBSTANCES ACT TITLE II--CONTROL AND ENFORCEMENT Part A--Short Title; Findings and Declaration; Definitions * * * * * * * definitions Sec. 102. As used in this title: (1) The term ``addict'' means any individual who habitually uses any narcotic drug so as to endanger the public morals, health, safety, or welfare, or who is so far addicted to the use of narcotic drugs as to have lost the power of self-control with reference to his addiction. (2) The term ``administer'' refers to the direct application of a controlled substance to the body of a patient or research subject by-- (A) a practitioner (or, in his presence, by his authorized agent), or (B) the patient or research subject at the direction and in the presence of the practitioner, whether such application be by injection, inhalation, ingestion, or any other means. (3) The term ``agent'' means an authorized person who acts on behalf of or at the direction of a manufacturer, distributor, or dispenser; except that such term does not include a common or contract carrier, public warehouseman, or employee of the carrier or warehouseman, when acting in the usual and lawful course of the carrier's or warehouseman's business. (4) The term ``Drug Enforcement Administration'' means the Drug Enforcement Administration in the Department of Justice. (5) The term ``control'' means to add a drug or other substance, or immediate precursor, to a schedule under part B of this title, whether by transfer from another schedule or otherwise. (6) The term ``controlled substance'' means a drug or other substance, or immediate precursor, included in schedule I, II, III, IV, or V of part B of this title. The term does not include distilled spirits, wine, malt beverages, or tobacco, as those terms are defined or used in subtitle E of the Internal Revenue Code of 1954. (7) The term ``counterfeit substance'' means a controlled substance which, or the container or labeling of which, without authorization, bears the trademark, trade name, or other identifying mark, imprint, number, or device, or any likeness thereof, of a manufacturer, distributor, or dispenser other than the person or persons who in fact manufactured, distributed, or dispensed such substance and which thereby falsely purports or is represented to be the product of, or to have been distributed by, such other manufacturer, distributor, or dispenser. (8) The terms ``deliver'' or ``delivery'' mean the actual, constructive, or attempted transfer of a controlled substance or a listed chemical, whether or not there exists an agency relationship. (9) The term ``depressant or stimulant substance'' means-- (A) a drug which contains any quantity of barbituric acid or any of the salts of barbituric acid; or (B) a drug which contains any quantity of (i) amphetamine or any of its optical isomers; (ii) any salt of amphetamine or any salt of an optical isomer of amphetamine; or (iii) any substance which the Attorney General, after investigation, has found to be, and by regulation designated as, habit forming because of its stimulant effect on the central nervous system; or (C) lysergic acid diethylamide; or (D) any drug which contains any quantity of a substance which the Attorney General, after investigation, has found to have, and by regulation designated as having, a potential for abuse because of its depressant or stimulant effect on the central nervous system or its hallucinogenic effect. (10) The term ``dispense'' means to deliver a controlled substance to an ultimate user or research subject by, or pursuant to the lawful order of, a practitioner, including the prescribing and administering of a controlled substance and the packaging, labeling, or compounding necessary to prepare the substance for such delivery. The term ``dispenser'' means a practitioner who so delivers a controlled substance to an ultimate user or research subject. (11) The term ``distribute'' means to deliver (other than by administering or dispensing) a controlled substance or a listed chemical. The term ``distributor'' means a person who so delivers a controlled substance or a listed chemical. (12) The term ``drug'' has the meaning given that term by section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act. (13) The term ``felony'' means any Federal or State offense classified by applicable Federal or State law as a felony. (14) The term ``isomer'' means the optical isomer, except as used in schedule I(c) and schedule II(a)(4). As used in schedule I(c), the term ``isomer'' means any optical, positional, or geometric isomer. As used in schedule II(a)(4), the term ``isomer'' means any optical or geometric isomer. (15) The term ``manufacture'' means the production, preparation, propagation, compounding, or processing of a drug or other substance, either directly or indirectly or by extraction from substances of natural origin, or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis, and includes any packaging or repackaging of such substance or labeling or relabeling of its container; except that such term does not include the preparation, compounding, packaging, or labeling of a drug or other substance in conformity with applicable State or local law by a practitioner as an incident to his administration or dispensing of such drug or substance in the course of his professional practice. The term ``manufacturer'' means a person who manufactures a drug or other substance. (16)(A) Subject to subparagraph (B), the terms ``marihuana'' and ``marijuana'' mean all parts of the plant Cannabis sativa L., whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin. (B) The terms ``marihuana'' and ``marijuana'' do not include-- (i) hemp, as defined in section 297A of the Agricultural Marketing Act of 1946; or (ii) the mature stalks of such plant, fiber produced from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mixture, or preparation of such mature stalks (except the resin extracted therefrom), fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination. (17) The term ``narcotic drug'' means any of the following whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (A) Opium, opiates, derivatives of opium and opiates, including their isomers, esters, whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designation. Such term does not include the isoquinoline alkaloids of opium. (B) Poppy straw and concentrate of poppy straw. (C) Coca leaves, except coca leaves and extracts of coca leaves from which cocaine, ecgonine, and derivatives of ecgonine or their salts have been removed. (D) Cocaine, its salts, optical and geometric isomers, and salts of isomers. (E) Ecgonine, its derivatives, their salts, isomers, and salts of isomers. (F) Any compound, mixture, or preparation which contains any quantity of any of the substances referred to in subparagraphs (A) through (E). (18) The term ``opiate''or ``opioid'' means any drug or other substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having such addiction-forming or addiction- sustaining liability. (19) The term ``opium poppy'' means the plant of the species Papaver somniferum L., except the seed thereof. (20) The term ``poppy straw'' means all parts, except the seeds, of the opium poppy, after mowing. (21) The term ``practitioner'' means a physician, dentist, veterinarian, scientific investigator, pharmacy, hospital, or other person licensed, registered, or otherwise permitted, by the United States or the jurisdiction in which he practices or does research, to distribute, dispense, conduct research with respect to, administer, or use in teaching or chemical analysis, a controlled substance in the course of professional practice or research. (22) The term ``production'' includes the manufacture, planting, cultivation, growing, or harvesting of a controlled substance. (23) The term ``immediate precursor'' means a substance-- (A) which the Attorney General has found to be and by regulation designated as being the principal compound used, or produced primarily for use, in the manufacture of a controlled substance; (B) which is an immediate chemical intermediary used or likely to be used in the manufacture of such controlled substance; and (C) the control of which is necessary to prevent, curtail, or limit the manufacture of such controlled substance. (24) The term ``Secretary'', unless the context otherwise indicates, means the Secretary of Health and Human Services. (25) The term ``serious bodily injury'' means bodily injury which involves-- (A) a substantial risk of death; (B) protracted and obvious disfigurement; or (C) protracted loss or impairment of the function of a bodily member, or organ, or mental faculty. (26) The term ``State'' means a State of the United States, the District of Columbia, and any commonwealth, territory, or possession of the United States. [(27) The term ``ultimate user'' means a person who has lawfully obtained, and who possesses, a controlled substance for his own use or for the use of a member of his household or for an animal owned by him or by a member of his household.] (27)(A) Except as provided in subparagraph (B), the term ``ultimate user'' means a person who has lawfully obtained, and who possesses, a controlled substance for the use by the person or for the use of a member of the household of the person or for an animal owned by the person or by a member of the household of the person. (B)(i) In the case of xylazine, other than for a drug product approved under subsection (b) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355), the term ``ultimate user'' means a person-- (I) to whom xylazine was dispensed by-- (aa) a veterinarian registered under this Act; or (bb) a pharmacy registered under this Act pursuant to a prescription of a veterinarian registered under this Act; and (II) who possesses xylazine for-- (aa) an animal owned by the person or by a member of the household of the person; (bb) an animal under the care of the person; (cc) use in government animal-control programs authorized under applicable Federal, State, Tribal, or local law; or (dd) use in wildlife programs authorized under applicable Federal, State, Tribal, or local law. (ii) In this subparagraph, the term ``person'' includes-- (I) a government agency or business where animals are located; and (II) an employee or agent of an agency or business acting within the scope of their employment or agency. (28) The term ``United States'', when used in a geographic sense, means all places and waters, continental or insular, subject to the jurisdiction of the United States. (29) The term ``maintenance treatment'' means the dispensing, for a period in excess of twenty-one days, of a narcotic drug in the treatment of an individual for dependence upon heroin or other mo

Source: https://api.congress.gov/v3/committee-report/119/hrpt/816